Cibus, Inc. (CBUS) company profile
Close on Nov 17, 2026Market cap $106.24MP/E –Yield –
About Cibus
Agricultural Chemicals, SIC 2870
Cibus develops proprietary plant traits using precision gene editing technologies, particularly its Rapid Trait Development System and Trait Machine process. The enterprise focuses primarily on licensing productivity traits, such as weed management and disease resistance, directly into seed companies' elite germplasm for royalty fees. Key agricultural programs target rice herbicide tolerance alongside trait initiatives across crops like canola, soybean, and wheat. Beyond core crop genetics, the organization maintains a sustainable ingredients line producing bio-based fragrance products through yeast fermentation for consumer packaged goods companies. Its customer base includes global seed producers and multinational corporate partners.
The entity maintains core operational activities and headquarters in San Diego, California, having streamlined staff and wound down a facility in Roseville, Minnesota. Its geographic footprint and commercial relationships span seed partners and field research programs across the United States, Latin America, Europe, the United Kingdom, and India.
Summary of the business section of Cibus's latest annual report, written by StockData.
Company profile
Company
- Legal name
- Cibus, Inc.
- Headquarters
- San Diego, CA
- Address
- 6455 Nancy Ridge Drive 92121
- Phone
- (858) 450-0008
- Website
- cibus.com
- Employees
- 118, Dec 31, 2025
- Industry
- Agricultural Chemicals
- Incorporated in
- Delaware
- Fiscal year ends
- December 31
- Auditor
- BDO USA, P.C., San Diego, California
Stock & identifiers
- Ticker
- CBUS
- Former tickers
- CLXT until Jun 1, 2023
- Exchange
- Nasdaq
- IPO date
- Jul 21, 2017
- Shares outstanding
- 76M, Aug 7, 2026
- Public float
- $47.16M, Jun 30, 2025
- Filer category
- Non-accelerated filer<br>Smaller reporting company
- Stock splits
- 1-for-5 reverse, Jun 1, 2023; 1-for-10 reverse, Apr 25, 2023
- SEC CIK
- 1705843
- CUSIP
- 17166A101
- ISIN
- US17166A1016
- FIGI
- BBG00H1CJS11
- Share class FIGI
- BBG00H1CJSR3
- EIN
- 27-1967997
Executives and directors
Officers and directors who filed ownership reports (Forms 3, 4, 5) in the last two years
| Name | Position | Shares owned |
|---|---|---|
| Carlo Broos | CFO | 225,935 |
| Jason Stokes | CAO, Gen Csl & Corp Secy | 164,346 |
| Noel Sauer | Sr VP, Research | 138,040 |
| Craig Wichner | CEO | 894,309 |
| Peter Beetham | Interim CEO, Pres & COO | 686,825 |
| Gregory Francis William Gocal | Chief Scientific Officer & EVP | 422,890 |
| Rory B. Riggs | Director | 14,982,312 |
| Kimberly Ann Box | Director | 0 |
| August J. Moretti | Director | 0 |
| Mark Terrence Finn | Director | 2,951,382 |
| Jean-Pierre Jules Lehmann | Director | 2,450,975 |
| Gerhard Prante | Director | 104,945 |
| Thomas Urban | Director | 64,748 |
| Keith Allen Walker | Director | 98,701 |
CEO pay and shareholder return
Pay versus performance table from the proxy statement
| Fiscal year | CEO total pay | CEO pay actually paid | Other executives (avg) | Value of $100 invested | Peer group |
|---|---|---|---|---|---|
| FY2025 Peter Beetham | $1.36M | $1.17M | $705.22K | $24 | – |
| FY2025 Rory Riggs | $302.36K | $200.10K | $705.22K | $24 | – |
| FY2024 | $500.01K | -$1.24M | $525.75K | $38 | – |
| FY2023 Michael Carr | $1.16M | $1.47M | $756.80K | $269 | – |
| FY2023 Rory Riggs | $292.31K | -$1.84M | $756.80K | $269 | – |
| FY2022 | $1.51M | -$322.67K | $856.10K | $7 | – |
“Actually paid” adjusts reported pay for changes in the value of equity awards. Shareholder return assumes $100 invested at the start of the measurement period, as disclosed by the company.
Executive compensation, fiscal 2025
Summary compensation table from the latest proxy statement
| Executive | Salary | Bonus | Stock awards | Option awards | Other | Total | vs. prior year |
|---|---|---|---|---|---|---|---|
| Peter Beetham Interim Chief Executive Officer, President, Chief Operating Officer, and Director | $630.58K | – | $276.10K | $457.67K | – | $1.36M | +173% |
| Rory Riggs Former Chief Executive Officer | $161.54K | – | – | $89.94K | $50.88K | $302.36K | -40% |
| Greg Gocal Chief Scientific Officer and Executive Vice President | $455.02K | $132.00K | $218.40K | – | – | $805.42K | +77% |
| Jason Stokes Chief Administrative Officer, General Counsel and Corporate Secretary | $439.71K | – | $62.15K | $103.15K | – | $605.01K | – |
Stock and option awards are grant-date fair values, not realized pay. “Other” includes pension value changes and all other compensation. Source proxy statement.
IPO
From the final prospectus (Form 424B4) and the first day of trading
Offering
- Type
- Initial public offering
- Final prospectus filed
- Jul 21, 2017
- Offer price
- $8.00
- Securities offered
- 7,000,000
- Gross proceeds
- $56.00M
- Exchange
- Nasdaq
- First trading day
- Jul 20, 2017
- First-day close
- $11.25+40.6%
- Lock-up ends (est.)
- Jan 16, 2018
“Our shares of common stock have been approved for listing on the NASDAQ Global Market (the “NASDAQ”) under the symbol “ CLXT .” The initial public offering price is $8.00 per share of common stock.”
Lock-up end is estimated as 180 days after the first trading day; the prospectus sets the actual terms.
Employees
Headcount reported in annual reports
“As of December 31, 2025, Cibus had 118 full-time employees, including a total of 29 employees with Ph.D.”
Corporate history
Events identified from SEC filings
| Date | Event | Details |
|---|---|---|
| Jun 1, 2023 | Acquisition / sale | Completion of acquisition or disposition of assets (8-K Item 2.01) |
| Jun 1, 2023 | Auditor change | Change in certifying accountant (8-K Item 4.01) |
| Jun 1, 2023 | Name change | Name changed from Calyxt, Inc. to Cibus, Inc. |
| Feb 14, 2023 | Merger | Registration of securities for a merger or exchange offer (S-4) |
| Oct 6, 2022 | Listing notice | Notice of delisting or failure to satisfy a listing rule (8-K Item 3.01) |
| May 20, 2022 | Listing notice | Notice of delisting or failure to satisfy a listing rule (8-K Item 3.01) |
| Jul 21, 2017 | IPO | Initial public offering priced (424B4 prospectus) |
| Jul 20, 2017 | Listing | Registration of securities on an exchange (Form 8-A) |
See a number that looks wrong?